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Progress with the
Affordable Care
Act (ACA)
Most of us have been following the
news concerning the ACA. The first open
enrollment period closed on March 31,
2014. A late surge pushed the number
of enrollees through the individual
marketplaces to about 8 million, which
exceeded Congressional Budget Office
(CBO) expectations. The coverage
gains mandated for young adults have
decremented their number without health
insurance by between 1 and 3 million.
All health care plans must now meet
comprehensive benefits standards (bronze,
silver, gold and platinum levels), and over
28 states and D.C. are moving forward on
Medicaid expansion.
For the individual marketplaces 8 million
new enrollees is the start, with the CBO
projecting up to 25 million gaining
insurance via the marketplaces by 2017.
Moreover, perhaps 5 million people
may gain coverage in 2014 directly from
insurers, partially prompted by the individual
mandate. Of note, the requirement that
enrollees use lower-priced providers
(narrow networks) and charge substantially
more when individuals go out of network
may prove challenging for the delivery of
tertiary surgical care at teaching hospitals.

When people think of skin cancer, they
often think of basal cell and squamous
cell cancers. But the deadliest form is
melanoma.
As surgical oncologist Adam Berger,
MD, FACS, explains, melanoma comes
from a different type of cell in the skin.
Unlike basal cell and squamous cell
cancers, which usually do not spread,
melanoma is much more aggressive. In
fact, while melanoma accounts for less
than 2 percent of skin cancer cases, it
causes a large majority of skin cancer
deaths.
In addition to melanoma excisions
(surgical removal of lesions), Dr. Berger
performs a diagnostic procedure
known as a sentinel lymph node biopsy.
With certain melanoma tumors most
likely to spread to the lymph nodes, this
procedure involves removal and testing
of a single node. Regardless of tumor
type, all melanoma patients need to be
followed closely over the long term due
to the aggressive nature of this cancer.

“...while melanoma
accounts for less
than 2 percent of
skin cancer cases,
it causes a large
majority of skin
cancer deaths.”

Overall, the CBO estimates that the ACA
will decrement the number of uninsured
in America by 26 million by 2017. Polls
suggest that the portion of U.S. adults
lacking insurance has fallen from 18% to
just 13% over the last year. The experience
varies by state, and those states not electing
to expand Medicaid are projected to have
less benefit. Finally, the sustainability of the
ACA depends upon many items, the most
important of which may be the ability to
sustain cost control across the spectrum
of care.

Jefferson participates in clinical
research to help advance the diagnosis
and treatment of melanoma. One such
trial is the MSLT-2 study – a follow-up
to the landmark MSLT-1 study that
established the sentinel node biopsy
as the standard for patients with
melanomas greater than a certain
depth. With patients across North
America, Europe and Australia –
including about 15 enrolled through
Jefferson – the MSLT-2 trial is testing
further surgical treatment following a
positive sentinel node biopsy.

Although estimates vary, somewhere
between 10 and 20 million Americans
appear to have gained coverage or have
enrolled in a new plan under the provisions
of the ACA since enrollment opened on
October 1, 2013. No matter where one sits
in the political spectrum, we as health care
providers (and as citizens of the U.S.) should
feel proud of this accomplishment.

“Today, when evidence of melanoma
is found in a lymph node, the next step
is to remove more lymph nodes,” Dr.
Berger explains. “In the MSLT2 trial, one
group of patients is having more nodes
removed, but the other is undergoing
a less invasive approach. Instead of
having more surgery, these patients
are being watched closely through
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Dr. Adam Berger, Director of the Section of Surgical Oncology in the Department of Surgery, specializes
in the surgical treatment of melanoma and encourages patients to take advantage of the clinical trials
underway at Jefferson.

ultrasound examination.” Patients in
this trial are now being followed, with
results expected in the next two to
three years.
Jefferson is also preparing to participate
in another clinical trial related
to melanoma. Sponsored by
biotechnology company Amgen, this
trial will test a vaccine designed to help
a patient’s own immune system fight
the spread of melanoma. The vaccine
will be injected in patients’ melanoma
lesions and their lymph nodes.

“The hypothesis is that the vaccine will
shrink the lesions themselves, and will
also offer protection for the rest of
the body,” Dr. Berger explains, adding
that the vaccine trial is slated to begin
patient enrollment later this year.

For more information about clinical trials
related to melanoma, please contact
Jamie Rothstein, clinical research nurse
and project manager for the Department
of Surgery, at 215-955-9359.

Meet Our Surgical Interns

The Department has welcomed an impressive new group of categorical interns,
three of which are graduates of Sidney Kimmel Medical College (formerly
Jefferson Medical College). The interns were selected from over one thousand
applicants to our program. These doctors, who recently matched with
Jefferson, started on June 20, 2014.
Please welcome (from left to right):
Kulvir Nandra, MD, Florida State University; Megan Lundgren, MD, Sidney
Kimmel Medical College; Jonathan Stem, MD, Wake Forest University; Christina
Jacovides, MD, University of Pennsylvania; Jennifer Kincaid, MD, Sidney
Kimmel Medical College; Will Chevrollier, MD, Sidney Kimmel Medical College.
We are also pleased to welcome back the following Sidney Kimmel Medical
College 2014 graduates as preliminary interns in general surgery: Daniel Hirsch,
MD, and Hong Truong, MD.

1

